NDA 022007 · Viatris Specialty
Perforomist
Formoterol Fumarate · Inhalation
Last checked: Nov 20, 2026Latest source record: May 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
May 11, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
514
215 Phase 3, 21 recruiting
FAERS reports
4,757
3,925 serious, 538 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2020.
Formoterol fumarate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • Formoterol fumarate inhalation solution is not indicated to treat asthma. ( 1.2 ) 1.1 Maintenance Treatment of COPD Formoterol fumarate inhalation solution is indicated for the long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. 1.2 Important Limitations of Use Formoterol fumarate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see Warnings and Precautions (5.2) ]. Formoterol fumarate inhalation solution is not indicated to treat asthma. The safety and effectiveness of formoterol fumarate inhalation solution in asthma have not been established.
Mechanism: Formoterol fumarate is a long-acting, beta 2 -adrenergic receptor agonist (beta 2 -agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist activity at beta 2 -receptors than at beta 1 -receptors. Although beta 2 -receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta 1 -receptors are the predominant receptors in the heart, there are also beta 2 -receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 11, 2007 Original approval · Type 3 - New Dosage Form Other Important Information from FDALetterLabel
1 products under this application
- PERFOROMIST · FORMOTEROL FUMARATE 0.02MG/2ML · SOLUTION, INHALATION · Prescription · TE AN
Clinical trials
Interventional ClinicalTrials.gov studies with "Formoterol" as an intervention, any sponsor and status, largest first.
- A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and AdolescentsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT01444430 · 12,460 participants · Start Dec 2011 · Primary completion Oct 2015
Drug: Symbicort pMDI; budesonide pMDI · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Anchorage, Alaska · 340 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02465567 · 8,588 participants · Start Jun 30, 2015 · Primary completion Jul 26, 2019
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 741 sites in all
- Local Phase 4 Pan-European SMART StudyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00463866 · 8,424 participants · Start Mar 2007
Drug: Budesonide/formoterol · For: Asthma
Sites: Aalst, Belgium; Aarschot, Belgium; Aatrijken, Belgium · 817 sites in all
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02224157 · 4,215 participants · Start Nov 28, 2014 · Primary completion Aug 16, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; budesonode bid + terbutaline 'as needed' · For: Asthma
Sites: Sydney, Australia; Botucatu, Brazil; Florianópolis, Brazil · 340 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02149199 · 3,850 participants · Start Jul 7, 2014 · Primary completion Aug 2, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; terbutaline 'as needed' + placebo budesonide bid and 1 more · For: Asthma
Sites: Bedford Park, Australia; Concord, Australia; Maroubra, Australia · 255 sites in all
- Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01911364 · 3,686 participants · Start Jan 2014 · Primary completion Mar 2016
Drug: BDP/FF/GB; Tiotropium and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Hessen, Germany; Szeged, Hungary; Perugia, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,333
- asthma1,150
- cough727
- wheezing608
- pneumonia530
- drug ineffective482
- therapeutic product effect incomplete461
- obstructive airways disorder430
- fatigue425
- headache405
- gastrooesophageal reflux disease393
- full blood count abnormal330
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 47 |
| 2006 | 66 |
| 2007 | 97 |
| 2008 | 66 |
| 2009 | 89 |
| 2010 | 106 |
| 2011 | 470 |
| 2012 | 457 |
| 2013 | 80 |
| 2014 | 69 |
| 2015 | 112 |
| 2016 | 141 |
| 2017 | 186 |
| 2018 | 222 |
| 2019 | 296 |
| 2020 | 359 |
| 2021 | 420 |
| 2022 | 372 |
| 2023 | 322 |
| 2024 | 288 |
| 2025 | 278 |
| 2026 | 185 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Perforomist (Formoterol Fumarate)
2024 spending
$459K
Beneficiaries
147
529 claims
Per beneficiary
$3,123
$9.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $10,625,078 |
| 2021 | $5,733,043 |
| 2022 | $1,945,394 |
| 2023 | $731,875 |
| 2024 | $459,128 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inhaled Reliever Therapies for Asthma: A Systematic Review and Meta-Analysis.
Rayner DG, Ferri DM, Guyatt GH, et al. · JAMA 2025 · Comparative Study, Research Support, N.I.H., Extramural
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.
O'Byrne PM, FitzGerald JM, Bateman ED, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hatter L, Holliday M, Oldfield K, et al. · Lancet 2025 · Multicenter Study, Randomized Controlled Trial
- As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma.
Bateman ED, Reddel HK, O'Byrne PM, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R, Holliday M, Reddel HK, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
Sponsor: Viatris Specialty
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.